News

The company targets end-stage renal disease (ESRD) and chronic kidney disease (CKD) with new products and services to treat iron replacement, secondary hyperparathyroidism and hemodialysis. Triferic is indicated

A portion of the CRADA research program is being sponsored by Intensity Therapeutics. CRADA will explore the processes by which the company’s products activate immune responses against cancer

MEDI7510 is composed of MedImmune’s RSV sF antigen plus GLA, a synthetic molecule licensed from Immune Design’s GLAAS discovery platform. This follows an existing agreement between the two

Tekmira is also conducting a separate Phase I/II clinical trial evaluating TKM-PLK1 in patients with Gastrointestinal Neuroendocrine Tumors (GI-NET) or Adrenocortical Carcinoma (ACC). "Hepatocellular carcinoma is associated with

The IND was filed by SCI with support from Stemedica Asia, a subsidiary of Stemedica, and was based on Stemedica’s United States FDA-approved Phase II AMI trial protocol.

The patent claims a novel form of rugged dsRNA. Rugged dsRNA are nucleic acids with a unique composition and physical characteristic identified with high specificity of binding to

The company’s ANDA product is a generic version of AstraZeneca and Bristol-Myers Squibb’s Onglyza, which is indicated as an adjunct to diet and exercise to improve glycemic control

The company secured exclusive global OTC rights to NEXIUM from British firm AstraZeneca in August 2012. Nexium 24HR (esomeprazole 20mg) was approved by the US Food and Drug

Solara Labs Founder & CEO, Dr. J. Rocca, remarked, "I am thrilled to bring our great-tasting, all-natural melts to the Bariatric community. The BariMelts brand represents our finest